CNR1 and inflammatory bowel disease: The studies using CB1R and CB2R agonist, and the inhibitors of MAGL and FAAH have shown encouraging results in mitigating gut inflammation in rodent models of IBD (Massa et al., 2004; Kimball et al., 2006; Storr et al., 2009; Alhouayek et al., 2011; Sałaga et al., 2014).